Letermovir cytomegalovirus prophylaxis in hematopoietic-cell transplantation; Real world evidence from high endemic regions. (ASH 2025) - Nov 4, 2025 - Abstract #abs25-11604; 4277; Pres time: Dec 7, 2025; 06:00 PM - 08:00 PM; Location: OCCC - West Halls B3-B4; "Patients were categorized intotwo groups:Study Group: Patients at ultra-high risk for CMV reactivation—defined as those who receivedhaploidentical or mismatched transplants, had R+/D− CMV serostatus, or received T-cell depletionwith anti-thymocyte globulin (ATG) or alemtuzumab (Campath)—who received letermovirprophylaxis and completed at least one year of post-transplant follow-up.Control Group: Patients with similar risk profiles who did not receive letermovir prophylaxis butcompleted at least one year of follow-up.The primary objective was to assess the proportion of patients with clinically significant CMV infection(csCMVi) through Week 24 post-transplant among those without detectable CMV DNA at baseline.Secondary objectives included:Proportion of patients with csCMVi through Week 14Time to csCMVi through Week 24Transplant-related mortality (TRM)Graft failureIncidence and severity of graft-versus-host disease (GVHD)Clinical and laboratory data were collected..."
Clinical • HEOR • Real-world • Real-world evidence • Bone Marrow Transplantation • Cytomegalovirus Infection • Genetic Disorders • Graft versus Host Disease • Hematological Disorders • Hematological Malignancies • Immunology • Infectious Disease • Leukemia • Sickle Cell Disease • Transplantation
|
|
Rahaf Salem1,2; Lama Alhmaly2,3; Bader Alahmari2,3; Ahmed Alaskar1,2; Husam AlSadi2,3; Ayman Almozaini2,3; Ayman Hejazi2,3; Abdullah S. Al Saleh2,3; Khalid AlHarbi2,3; Mashael AlMutairi2,3; Mazin Ahmed3,4; Nourah Alshuraym2,3; MAYBELLE BALILI1,2; Mohsen Alzahrani2,3
|